DK0536350T3 - Identifikation af et nyt humant receptor-tyrosinkinase-gen - Google Patents

Identifikation af et nyt humant receptor-tyrosinkinase-gen

Info

Publication number
DK0536350T3
DK0536350T3 DK92907369T DK92907369T DK0536350T3 DK 0536350 T3 DK0536350 T3 DK 0536350T3 DK 92907369 T DK92907369 T DK 92907369T DK 92907369 T DK92907369 T DK 92907369T DK 0536350 T3 DK0536350 T3 DK 0536350T3
Authority
DK
Denmark
Prior art keywords
receptor
receptor tyrosine
tyrosine kinase
identification
kinase gene
Prior art date
Application number
DK92907369T
Other languages
English (en)
Inventor
Bruce Israel Terman
Miguel Eduardo Carrion
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of DK0536350T3 publication Critical patent/DK0536350T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
DK92907369T 1991-02-22 1992-02-20 Identifikation af et nyt humant receptor-tyrosinkinase-gen DK0536350T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65723691A 1991-02-22 1991-02-22
PCT/US1992/001300 WO1992014748A1 (en) 1991-02-22 1992-02-20 Identification of a novel human receptor tyrosine kinase gene

Publications (1)

Publication Number Publication Date
DK0536350T3 true DK0536350T3 (da) 2002-09-02

Family

ID=24636385

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92907369T DK0536350T3 (da) 1991-02-22 1992-02-20 Identifikation af et nyt humant receptor-tyrosinkinase-gen

Country Status (8)

Country Link
EP (1) EP0536350B1 (da)
AT (1) ATE221915T1 (da)
CA (1) CA2083401C (da)
DE (1) DE69232718T2 (da)
DK (1) DK0536350T3 (da)
ES (1) ES2180535T3 (da)
SG (1) SG49753A1 (da)
WO (1) WO1992014748A1 (da)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
AU3482493A (en) * 1992-01-22 1993-09-01 New England Deaconess Hospital Novel protein tyrosine kinases
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US5776755A (en) * 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
CA2145985C (en) * 1992-10-28 2003-09-16 Napoleone Ferrara Vascular endothelial cell growth factor antagonists
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US6872699B2 (en) 1992-11-13 2005-03-29 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften, E.V. Truncated Flk-1 receptor protein, methods of use and a recombinant vector containing a nucleotide encoding the truncated Flk-1 protein
CA2158745C (en) * 1993-03-25 2007-06-19 Richard L. Kendall Inhibitor of vascular endothelial cell growth factor
US6001621A (en) * 1993-11-23 1999-12-14 Genetech, Inc. Protein tyrosine kinases
AU697142B2 (en) 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
ES2249762T3 (es) 1994-03-08 2006-04-01 Human Genome Sciences, Inc. Factor de crecimiento del endotelio vascular 2.
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
AU710696C (en) 1995-09-08 2002-10-24 Genentech Inc. VEGF-related protein
WO1997017442A1 (en) 1995-11-08 1997-05-15 Immunex Corporation Flk-1 binding protein
US6994989B1 (en) 1995-11-08 2006-02-07 Immunex Corp. FLK-1 binding proteins
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
DE69635740T2 (de) * 1995-12-18 2006-09-14 Sugen, Inc., South San Francisco Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
GB9601640D0 (en) * 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
WO1998058053A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
WO2000021560A1 (en) 1998-10-09 2000-04-20 Ludwig Institute For Cancer Research Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY
DK1140173T4 (da) 1998-12-22 2013-06-10 Genentech Inc Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
WO2000064946A2 (en) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
NZ518077A (en) 2000-08-04 2003-11-28 Human Genome Sciences Inc Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
ATE359300T1 (de) 2001-01-19 2007-05-15 Ludwig Inst Cancer Res Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7985402B2 (en) 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
SI2949658T1 (sl) 2003-03-03 2018-10-30 Dyax Corp. Peptidi, ki specifično vežejo HGF receptor (cMet) in njihove uporabe
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
ES2523457T3 (es) 2004-11-18 2014-11-26 Imclone Llc Anticuerpos contra el receptor 1 del factor de crecimiento endotelial vascular
CL2008003449A1 (es) 2007-11-21 2010-02-19 Imclone Llc Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer.
US9745558B2 (en) 2013-02-18 2017-08-29 Vegenics Pty Limited VEGFR-3 ligand binding molecules and uses thereof

Also Published As

Publication number Publication date
DE69232718T2 (de) 2003-04-03
ATE221915T1 (de) 2002-08-15
ES2180535T3 (es) 2003-02-16
CA2083401C (en) 2003-03-25
EP0536350B1 (en) 2002-08-07
EP0536350A4 (en) 1994-03-22
WO1992014748A1 (en) 1992-09-03
DE69232718D1 (de) 2002-09-12
EP0536350A1 (en) 1993-04-14
CA2083401A1 (en) 1992-08-23
SG49753A1 (en) 1998-06-15

Similar Documents

Publication Publication Date Title
DK0536350T3 (da) Identifikation af et nyt humant receptor-tyrosinkinase-gen
IL191078A0 (en) POLYPEPTIDES WHICH BIND TO ErbB3 OR ErbB4 RECEPTOR PROTEIN TYROSINE KINASE OR BOTH, NUCLEIC ACIDS, VECTORS, HOST CELLS, COMPOSITIONS, METHOD FOR PRODUCTION AND USE OF SUCH POLYPEPTIDES
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
BR0009721A (pt) Inibidores de tirosina quinase de proteìna cìclica
DE69838334D1 (de) Kdr, ein menschlicher tyrosin kinase rezeptor
NO975956D0 (no) Pyrrolopyrimidiner og fremgangsmåter for deres fremstilling
ATE389666T1 (de) Hohe expressionsrate von proteinen
CY2451B1 (en) Fused heterocyclic compunds as protein tyrosine kinase inhibitors.
ATE324441T1 (de) Htk-ligand
ES2133800T3 (es) Pirimido(5,4-d)pirimidinas, medicamentos que contienen estos compuestos, su uso y su procedimiento de preparacion.
DK0590071T3 (da) Hovedsagelig rene receptor-lignende TGF-BETA-1 bindende molekyler samt anvendelse deraf
ATE153858T1 (de) Ligand für das neu-gen-produkt
ATE469981T1 (de) Tests auf proteinkinasen mit fluoreszierenden proteinsubstraten
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
EA200301005A1 (ru) Замещенные в положении 6 индолиноны и их применение в качестве ингибиторов киназ
BR9910787A (pt) Métodos e composições úteis para modulação deangiogênese usando tirosina cinase src
DK0583338T3 (da) Fremgangsmåde til syntese af peptider, hidtil ukendte aminosyrederivater anvendt i denne fremgangsmåde og fremgangsmåder til deres fremstilling
DE60139113D1 (de) 18477, eine menschliche proteinkinase und deren verwendung
PT906425E (pt) Moleculas de ligacao a aminas vasoactivas
ATE262584T1 (de) Verwendung eines inhibitors von tau/neurofilament-proteinkinase pk40
DE59207008D1 (de) Klonierung eines neuen mitgliedes der familie der fibroblasten-wachstumsfaktoren (fgf)-rezeptoren
DE60011785D1 (de) Verfahren zur herstellung von proteinen in wirtszellen unter verwendung von chaperoninen
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
SE9604439D0 (sv) New receptor
DK1064389T3 (da) Sammensætninger med fusionsproteiner af kinase Wee1, nukleotidsekvenser, ekspressionssystemer og fremgangsmåder til deres anvendelse